A novel preservative-free seasonal influenza vaccine safety and immune response study in the frame of preclinical research.
The paper describes the results of preclinical testing of the preparation "Vaccine allantoic split-virus inactivated against seasonal influenza." Acute toxicity and local irritating effect, anaphylactic reactions to different antigens (vaccine and ovalbumin), delayed-type hypersensitivity to ram erythrocytes, humoral immune response in hemaggtination reaction, immunogenic activity was studied in laboratory animals of various species (mice, rats, guinea pigs). Comparative analysis of the results from testing immunogenic activity of the preparation under study and the commercial influenza vaccines was performed. The preclinical testing has demonstrated safety and immune response of the seasonal split influenza vaccine, so it may be recommended for clinical study on limited contingent of volunteers.
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Gulbanu
0000-0002-1310-3936
G
Sarsenbayeva
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Yevgeniy
Y
Volgin
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Markhabat
M
Kassenov
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Timur
T
Issagulov
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Nikolay
N
Bogdanov
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Ainur
A
Nurpeisova
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Altynay
A
Sagymbay
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Ruslan
R
Abitay
Influenza Research Institute, St.Petersburg, Russian Federation.
Marina
M
Stukova
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Abylay
A
Sansyzbay
Research Institute for Biological Safety Problems, Gvardeysk, Kazakhstan.
Berik
B
Khairullin
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D004353:Drug Evaluation, Preclinical; D004912:Erythrocytes; D006168:Guinea Pigs; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000517:prevention & control; D000071497:Immunogenicity, Vaccine; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000737:chemistry / Q000276:immunology*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D011310:Preservatives, Pharmaceutical; D051381:Rats; D012621:Seasons; D012756:Sheep; D015164:Vaccines, Inactivated / Q000009:adverse effects / Q000276:immunology
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D011310:Preservatives, Pharmaceutical; D015164:Vaccines, Inactivated
acute toxicity; hypersensibility; immunotoxicity; influenza